Hana ʻo AASraw i nā pauka NMN a me NRC i ka nui!

ʻO Erlotinib

Rating: Māhele:

ʻO Erlotinib Powder, kūʻai ʻia ma lalo o ka inoa ʻo Tarceva i waena o nā mea ʻē aʻe, kahi lāʻau i hoʻohana ʻia e mālama ai i ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) a me ka maʻi ʻaʻai pancreatic. Hoʻohana kikoʻī ʻia ia no NSCLC me nā hoʻololi ʻana i ka receptor ulu ulu epidermal (EGFR) - a i ʻole he exon 19 holoi ʻia (del19) a i ʻole exon 21 (L858R) substation mutation - i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino.

Product Description

Nā ʻano kikoʻī

Product Name Pauka Erlotinib
Kāleka CAS 183321-74-6
Ka Lā Molecular C22H23N3O4
Kaumaha Kaumaha 393.443
'O Synonyms CP-358774;

OSI774;

Kahua kumu manuahi Erlotinib;

183321-74-6.

Keʻano ʻO ka'ōmaʻomaʻo o ka māmā
Ka mālama a me ka lima lima Maloʻo, ʻeleʻele a ma 0 - 4 C no ka wā pōkole (mau lā a i mau pule) a i ʻole -20 C no ka wā lōʻihi (mau mahina i mau makahiki).

 

Hōʻike Powder Erlotinib

ʻO ka pauma Erlotinib, kūʻai ʻia ma lalo o ka inoa ʻo Tarceva i waena o nā mea ʻē aʻe, kahi lāʻau i hoʻohana ʻia e mālama ai i ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) a me ka maʻi ʻaʻai pancreatic. Hoʻohana kikoʻī ʻia ia no NSCLC me nā hoʻololi ʻana i ka receptor ulu ulu epidermal (EGFR) - a i ʻole he exon 19 holoi ʻia (del19) a i ʻole exon 21 (L858R) substation mutation - i pāhola ʻia i nā ʻāpana ʻē aʻe o ke kino. Lawe ʻia e ka waha.

ʻO ka paukū Erlotinib kahi huahana quinazoline me nā ʻano antineoplastic. Ke hoʻokūkū nei me ka adenosine triphosphate, hoʻopili ʻo erlotinib pauka i ka wahi catalytic intracellular o ka receptor (EGFR) tyrosine kinase receptor (EGFR) tyrosine kinase, a me ka pale ʻana i nā hanana transtruction signal a me nā hopena tumigenic e pili ana me ka hoʻoulu ʻana o EGFR.

Ua ʻae ʻia ʻo Erlotinib pauka no ka hoʻohana olakino maʻAmelika Hui Pū ʻIa i 2004. Aia ia ma ka Papa Inoa o nā Pono Ola Loa o ka Honua Hui Pū ʻIa, e hōʻike nei i nā lāʻau ʻoi aku ka palekana a maikaʻi hoʻi e pono ai i kahi ʻōnaehana olakino.

 

ʻO Erlotinib Powder Mekanism o ka Hana

ʻO ka paukū Erlotinib kahi mea ulu kūpona epidermal receptor (inhibitor EGFR). Hāpai ka lāʻau iā Iressa (gefitinib), ʻo ia ka lāʻau mua o kēia ʻano.

Hoʻopaʻa pololei ʻo Erlotinib pauka i ka mea ulu epidermal factor receptor (EGFR) tyrosine kinase, i hōʻike nui ʻia a hoʻololi ʻia i kekahi manawa i nā ʻano ʻano like ʻole o ka maʻi ʻaʻai. Hoʻopili ia i kahi ʻano hiki ke hoʻi i ka adenosine triphosphate (ATP) pūnaewele paʻa o ka mea loaʻa. No ka lawe ʻia ʻana o ka hōʻailona, ​​pono e ʻākoakoa ʻelua mau moleka EGFR e hana i homodimer.

Hoʻohana kēia i ka mole o ATP e trans-phosphorylate kekahi i kekahi ma nā koena tyrosine, kahi e hoʻoulu ai i nā koena phosphotyrosine, e ʻohi nei i nā protein-hoʻopaʻa paʻa phospotyrosine iā EGFR e hōʻuluʻulu i nā pāʻina protein i lawe i nā cascades hōʻailona i ka nucleus a i ʻole hana i nā hana bichemical pūnaewele. Ke nakinaki ʻia ka pauma erlotinib i ka EGFR, ʻaʻole hiki ke hoʻokumu ʻia nā koena phosphotyrosine i EGFR a ʻaʻole i hoʻomaka ʻia nā cascades hōʻailona.

ʻO ka paukū Erlotinib kahi pauka receptor tyrosine kinase i hoʻohana ʻia i ka hoʻomaʻamaʻa ʻana i ka pancreatic holomua a metastatic a i ʻole ka maʻi ʻaʻa maʻi liʻiliʻi liʻiliʻi. Hoʻopili ʻia ʻo Erlotinib paukū therapy me nā kiʻekiʻe kiʻekiʻe i nā pae aminotransferase serum i ka wā o ka therapy a me nā hanana kakaikahi e ʻike ʻia ai ka ʻehaʻeha o ke ake.

 

ʻO ka noi Powder Erlotinib 

ʻO ka pauma Erlotinib kahi receptor tyrosine kinase inhibitor hanauna mua (me Gefitinib) e hana nui ana i ka mea ulu ulu epidermal (EGFR), kahi lālā o ka ʻohana receptor ErbB. Hoʻopili ka lāʻau me ka ʻano hihiu a me ka hoʻololi EGFR. Hiki i ka ʻohana ErbB ke hana i nā homodimers a i ʻole heterodimers, i hoʻopili pinepine ʻia i nā hopena kahe a me nā pathogenesis o nā ʻano carcinomas i hoʻopaʻa ʻia i loko o nā kānaka. ʻO nā mea hoʻokiʻoki tyrosine kinase mea hōʻemi (TKI) pale i ka phosphorylation o kā lākou substrate i ke ala hōʻailona o ke kelepona. Hana nui ʻo EGFR i nā hana pūnaewele, e like me ka hoʻokaʻawale ʻana, ka hoʻolaha ʻana, a me ka angiogenesis, nā hiʻohiʻona āpau o ka maʻi ʻaʻai.

ʻO ka hoʻololi EGFR ma NSCLC kahi hoʻololi pinepine. ʻO kekahi mau ʻano hoʻomanawanui e pili ana i ka hoʻololi ʻana o ka EGFR me ka ʻole o ka mōʻaukala i hōʻoia ʻia adenocarcinoma e ka loiloi histologic, ka lāhui ʻĀkia, a me ka wahine wahine. Kū pinepine nā hoʻololi ʻē aʻe i ka EGFR, ka mea a kēia ʻatikala e hōʻike nei ma lalo.

 

Nā hopena a me nā ʻōlelo aʻoaʻo a Erlotinib Powder

ʻO nā hopena ʻē aʻe e maʻa mau no nā mea maʻi e lawe ana iā Erlotinib Powder:

▪ Kahiki

▪ Pohā

▪ Makemake maikaʻi ʻole

▪ Luhi

▪ Ka liʻiliʻi o ka hanu

▪ Mākeke

▪ Kaʻuā a me ka luaʻi

 

ʻO kēia mau hopena a ʻoi aku ka hopena o ka hopena o nā mea maʻi e loaʻa ana iā Erlotinib Powder:

▪ maʻi ʻaʻai

▪ Wela ka waha

▪ Kāwili

▪ ʻili maloʻo

▪ Hoʻonāukiuki maka

▪ ʻeha ʻōpū

 

ʻAʻole i helu ʻia nā hopena ʻaoʻao āpau ma luna. Kākaʻikahi kekahi mau mea (e hana ana ma lalo o 10% o nā maʻi) ʻaʻole i helu ʻia ma aneʻi. Eia nō naʻe, pono ʻoe e hoʻomaopopo mau i kāu mea mālama ola inā ʻike ʻoe i nā ʻōuli maʻamau.

 

Reference

[1] ʻO Gao JW, Zhan P, Qiu XY, Jin JJ, Lv TF, Song Y. Erlotinib i hoʻokumu ʻia i hana ʻia me ka pauka erlotinib wale nō i mālama mua ʻia me ka maʻi ʻaʻaʻa liʻiliʻi liʻiliʻi ʻole. nā hoʻāʻo i kāohi ʻia. Oncotarget. 24 Mei 2017; 31 (8): 42-73258. hana: 73270 / oncotarget.10.18632. eCollection 18319 Sep 2017. Loiloi. PubMed PMID: 22; PubMed Central PMCID: PMC29069867.

[2] Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T , Yang JC. ʻO Gefitinib a i ʻole Erlotinib pauma vs Chemotherapy no ka EGFR Mutation-Positive Lung Cancer: Meta-Data Data Patient Patient o ke ola holoʻokoʻa. ʻO J Natl Cancer Inst. 2017 Jun 1; 109 (6). hana: 10.1093 / jnci / djw279. Loiloi. ʻO PubMed PMID: 28376144.

[3] Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J. Hoʻohālikelike o gefitinib, erlotinib pauma a me afatinib i ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi: He meta-analysis. Int J Ka maʻi ʻaʻai. 2017 Jun 15; 140 (12): 2805-2819. hana: 10.1002 / ijc.30691. Epub 2017 Mar 27. Loiloi. ʻO PubMed PMID: 28295308.

[4] "Erlotinib pauka (Tarceva) e hoʻohana ai i ka wā o ka hāpai keiki". ʻO Drugs.com. 1 Nowemapa 2019. Ua kiʻi ʻia 23 December 2019.

[5] "Erlotinib pauka Monograp no nā Pâʻani". ʻO Drugs.com. Ua kiʻi ʻia 12 Nowemapa 2019.

[6] "Tarceva- erlotinib pauka hydrochloride papa". DailyMed. 12 Kekemapa 2018. Loaʻa iā 23 Kekemapa 2019.

[7] "Pahu ʻApono ʻAi: Tarceva (Erlotinib pauka) NDA # 021743". ʻO ka US Food and Drug Administration (FDA). 28 Malaki 2005. Ua kiʻi ʻia 23 Kekemapa 2019.

[8] Raymond E, Faivre S, Armand JP (2000). "ʻO ka ulu ulu Epidermal receptor tyrosine kinase ma ke ʻano he māka no ka anticancer therapy". Nā lāʻau. 60 Hōʻawi 1: 15–23, kūkā 41-2. hana: 10.2165 / 00003495-200060001-00002. PMID 11129168. S2CID 10555942.


 

  • ʻO Acalabrutinib (ACP-196)Free heluhelu hou
  • Afatinib (BIBW2992)Free heluhelu hou
  • ʻO CabozantinibFree heluhelu hou